Trends in molecular medicine, 2017-05, Vol.23 (5), p.377-378
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers
- Ist Teil von
- Trends in molecular medicine, 2017-05, Vol.23 (5), p.377-378
- Ort / Verlag
- England: Elsevier Ltd
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1471-4914eISSN: 1471-499XDOI: 10.1016/j.molmed.2017.03.005Titel-ID: cdi_proquest_miscellaneous_1884164875
- Format
- –
- Schlagworte
- Allelic Imbalance - genetics, Benzamides - pharmacology, Diphenylamine - analogs & derivatives, Diphenylamine - pharmacology, Gene Dosage - genetics, Humans, Leukemia - genetics, MAP Kinase Kinase 1 - antagonists & inhibitors, MAP Kinase Kinase 1 - metabolism, MAP Kinase Kinase 2 - antagonists & inhibitors, MAP Kinase Kinase 2 - metabolism, Models, Theoretical, Pathology, Proto-Oncogene Proteins p21(ras) - genetics